Clinical trials: Stage II Lung Cancer
Non-small Cell Lung Cancer Metastatic
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT…
- Trial name
- NCT01935154
- Testing
- Vx-001
- Where
- 70 sites in Czechia, France and 6 more
- Volunteers
- 221 people
- Sponsor
- Vaxon Biotech
Lung Cancer
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung…
- Trial name
- NCT00057746
- Testing
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Where
- 222 sites in United States, Canada
- Volunteers
- 265 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial…
- Trial name
- Geometry-N (NCT04926831)
- Testing
- capmatinib
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
SCION: SABR and Checkpoint Inhibition of NSCLC
The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer. The purpose of the trial is to investigate whether it is safe and effective to combine standard radiation treatment with a drug called…
- Conditions
- Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer Stage I, Lung Cancer
- Trial name
- SCION (NCT04944173)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Circulating Tumor DNA assay
- Where
- 5 sites in Canada
- Sponsor
- University of British Columbia
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8
- Trial name
- NCT04158141
- Testing
- Carboplatin, Cisplatin, Decortication
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- NRG Oncology
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Neoplasms
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus…
- Trial name
- NCT06926673
- Testing
- Dostarlimab, Belrestotug., Nelistotug
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline
Non-Small-Cell Lung Cancer
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Determine tumor response rate and time to disease progression, survival and safety in total populations.
- Trial name
- NCT00063388
- Testing
- Cetuximab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Lung Neoplasm
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
Investigations prospectively collected the SCLC patients who received current standard first-line treatment, the response was not progression disease(PD).
- Conditions
- Carcinoma, Lung Neoplasm, Small Cell Lung Cancer
- Trial name
- NCT03780283
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Hospital of Shijiazhuang City
Lung Cancer
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
The purpose of this study is: To find out if the chemotherapy treatment using Pemetrexed (Alimta) and Oxaliplatin (Eloxatin) given together will kill the cancer cells in the patient's body and shrink the size of their tumor.
- Trial name
- NCT00612677
- Testing
- Oxaliplatin, Pemetrexed
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens: weekly docetaxel plus cisplatin followed by gemcitabine; and gemcitabine plus cisplatin followed by weekly…
- Trial name
- NCT00173888
- Testing
- Docetaxel, Cisplatin, Gemcitabine, Cisplatin
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer, Carcinoma, Non-Small-Cell Lung
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded…
- Trial name
- NCT00238615
- Testing
- Docetaxel, Carboplatin, Radiation therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Carcinoma, Non-Small-Cell Lung
A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer
Primary to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens: 1. weekly docetaxel plus cisplatin followed by gemcitabine and 2. gemcitabine plus cisplatin followed by weekly docetaxel.
- Trial name
- NCT00270582
- Testing
- Taxotere, Cisplatin, Gemcitabine
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Far Eastern Memorial Hospital
NSCLC
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
This study is a prospective, multicenter, open-label, single-arm Phase II clinical trial. The study recruits patients with stage III unresectable non-small cell lung cancer according to the 8th edition of the AJCC/UICC staging…
- Trial name
- NCT07082179
- Testing
- Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum (cisplatin/carboplatin)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Non-small Cell Lung Cancer
Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy
- Trial name
- NCT04144582
- Testing
- Sintilimab Combined With Docetaxel Monotherapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Yongchang Zhang
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04919382
- Testing
- Atezolizumab, Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dwight Owen
Lung Non-Small Cell Carcinoma
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently…
- Trial name
- NCT07323641
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06632327
- Testing
- Surgical Procedure, Cisplatin, Carboplatin
- Where
- 415 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced or Metastatic NSCLC
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and…
- Trial name
- LOTOS (NCT05941897)
- Testing
- Ceralasertib, Durvalumab
- Where
- 8 sites in Russia
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Resectable NSCLC, KRAS G12C Mutation
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung…
- Conditions
- Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
- Trial name
- K-NADIR (NCT07492342)
- Testing
- fulzerasib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Jianxing He